Company · CIK 0001651308 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
BeOne Medicines Ltd. · ONC
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2017 MForm 4 → | Dec 22, 4:43 pm EST | Jane HuangCMO, Hematology | 1,000 | $29.51 | $29,510 | 1,000 | — | plan? |
| Dec 13, 2017 SForm 4 → | Dec 15, 4:05 pm EST | Jane HuangCMO, Hematology | 1,500 | $94.25 | $141,381 | 0 | −100% | plan? |
| Dec 13, 2017 MForm 4 → | Dec 15, 4:05 pm EST | Jane HuangCMO, Hematology | 1,500 | $29.51 | $44,265 | 1,500 | — | plan? |
| Dec 6, 2017 SForm 4 → | Dec 8, 5:57 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 144,000 | $93.95 | $13,529,286 | 119,137 | −54.7% | plan? |
| Dec 4, 2017 SForm 4 → | Dec 5, 9:15 am EST | Jane HuangCMO, Hematology | 1,100 | $86.00 | $94,600 | 0 | −100% | plan? |
| Nov 27, 2017 SForm 4 → | Nov 29, 5:33 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 85,906 | $84.66 | $7,272,904 | 263,137 | −24.6% | plan? |
| Nov 16, 2017 SForm 4 → | Nov 20, 5:14 pm EST | Jane HuangCMO, Hematology | 1,600 | $86.25 | $138,000 | 1,100 | −59.3% | plan? |
| Nov 13, 2017 SForm 4 → | Nov 15, 8:12 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 150,957 | $80.50 | $12,152,374 | 349,043 | −30.2% | plan? |
| Nov 13, 2017 SForm 4 → | Nov 15, 8:11 pm EST | Amy C. PetersonCMO, Immuno-oncology | 3,601 | $82.96 | $298,747 | 0 | −100% | plan? |
| Oct 13, 2017 JForm 4 → | Oct 16, 5:47 pm EDT | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 63,404 | — | — | 7,102 | — | plan? |
| Sep 27, 2017 AForm 4 → | Oct 2, 7:10 am EDT | John OylerChief Executive Officer, Director, 10% Owner | 515,000 | — | — | 21,745,525 | — | plan? late |
| Sep 27, 2017 AForm 4 → | Oct 2, 6:41 am EDT | Xiaodong WangDirector | 410,000 | — | — | 12,935,393 | — | plan? late |
| Aug 22, 2017 FForm 4 → | Aug 24, 4:20 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 28,185 | $5.39 | $151,830 | 271,815 | — | plan? |
| Aug 11, 2017 PForm 4 → | Aug 14, 3:49 pm EDT | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 176,056 | $71.00 | $12,499,976 | 3,476,256 | +5.33% | plan? |
| Jul 31, 2017 GForm 5 → | Feb 13, 2018, 4:27 pm EST | Donald W. GlazerDirector | 27,287 | — | — | 4,538,507 | — | plan? |
| Jul 12, 2017 SForm 4 → | Jul 13, 6:31 pm EDT | Xiaodong WangDirector | 20,000 | $72.44 | $1,448,704 | 0 | −100% | plan? |
| Jul 11, 2017 GForm 4 → | Jul 12, 9:37 pm EDT | Donald W. GlazerDirector | 175,682 | — | — | 4,565,794 | — | plan? |
| Jul 10, 2017 SForm 4 → | Jul 12, 9:37 pm EDT | Donald W. GlazerDirector | 10,810 | $72.15 | $779,900 | 0 | −100% | plan? |
| Jul 6, 2017 SForm 4 → | Jul 10, 6:44 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 219,400 | $64.82 | $14,221,125 | 0 | −100% | plan? |
| Jun 28, 2017 SForm 4 → | Jun 30, 4:36 pm EDT | Xiaodong WangDirector | 35,000 | $44.95 | $1,573,345 | 20,000 | −63.6% | plan? |
| Jun 22, 2017 SForm 4 → | Jun 26, 8:38 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 98,500 | $44.16 | $4,349,622 | 46,840 | −67.8% | plan? |
| Jun 2, 2017 SForm 4 → | Jun 6, 4:20 pm EDT | Xiaodong WangDirector | 5,539 | $40.00 | $221,560 | 55,000 | −9.15% | plan? |
| May 11, 2017 GForm 4 → | Jun 6, 4:20 pm EDT | Xiaodong WangDirector | 29,523 | — | — | 224,372 | — | plan? late |
| May 3, 2017 SForm 4 → | May 5, 5:50 pm EDT | Xiaodong WangDirector | 14,461 | $40.80 | $590,042 | 60,539 | −19.3% | plan? |
| Apr 27, 2017 SForm 4 → | May 1, 7:44 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 36,149 | $40.47 | $1,462,808 | 145,340 | −19.9% | plan? |
| Apr 5, 2017 SForm 4 → | Apr 7, 5:10 pm EDT | Xiaodong WangDirector | 11,650 | $36.83 | $429,085 | 75,000 | −13.4% | plan? |
| Mar 22, 2017 SForm 4 → | Mar 24, 6:57 pm EDT | Xiaodong WangDirector | 38,107 | $36.96 | $1,408,612 | 86,650 | −30.5% | plan? |
| Mar 16, 2017 SForm 4 → | Mar 20, 7:06 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 31,989 | $39.39 | $1,260,073 | 181,489 | −15.0% | plan? amended |
| Mar 8, 2017 SForm 4 → | Mar 10, 7:16 pm EST | Xiaodong WangDirector | 36,892 | $39.89 | $1,471,756 | 124,757 | −22.8% | plan? |
| Mar 2, 2017 SForm 4 → | Mar 6, 7:00 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 108,999 | $40.91 | $4,459,330 | 213,478 | −33.8% | plan? |
| Feb 23, 2017 SForm 4 → | Feb 27, 9:11 pm EST | Xiaodong WangDirector | 38,351 | $38.19 | $1,464,793 | 161,649 | −19.2% | plan? |
| Feb 16, 2017 SForm 4 → | Feb 21, 7:23 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 64,963 | $40.55 | $2,634,011 | 322,477 | −16.8% | plan? |
| Nov 23, 2016 SForm 4 → | Nov 28, 4:04 pm EST | Xiaodong WangDirector | 93,750 | $32.00 | $3,000,000 | 0 | −100% | plan? |
| Nov 23, 2016 PForm 4 → | Nov 28, 4:02 pm EST | Thomas MalleyDirector | 30,000 | $32.00 | $960,000 | 30,000 | — | plan? |
| Nov 18, 2016 PForm 4 → | Nov 21, 6:13 pm EST | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 1,760,495 | $32.00 | $56,335,840 | 3,317,977 | +113% | plan? |
| Sep 28, 2016 SForm 4 → | Sep 30, 4:50 pm EDT | Donald W. GlazerDirector | 41,463 | $30.66 | $1,271,175 | 0 | −100% | plan? |
| Sep 26, 2016 SForm 4 → | Sep 28, 4:11 pm EDT | Donald W. GlazerDirector | 47,149 | $29.61 | $1,395,992 | 41,463 | −53.2% | plan? |
| Sep 22, 2016 SForm 4 → | Sep 26, 6:12 pm EDT | Donald W. GlazerDirector | 36,443 | $31.02 | $1,130,355 | 88,612 | −29.1% | plan? |
| Sep 19, 2016 SForm 4 → | Sep 21, 9:11 pm EDT | Donald W. GlazerDirector | 67,252 | $31.42 | $2,113,061 | 125,055 | −35.0% | plan? |
| Sep 2, 2016 AForm 4 → | Sep 7, 5:13 pm EDT | Jane HuangCMO, Hematology | 300,000 | — | — | 300,000 | — | plan? |
| Aug 22, 2016 AForm 4 → | Aug 24, 6:12 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 300,000 | — | — | 300,000 | — | plan? |
| Jul 7, 2016 GForm 4 → | Sep 21, 9:11 pm EDT | Donald W. GlazerDirector | 250,003 | — | — | 4,881,997 | — | plan? late |
| May 3, 2016 AForm 4 → | May 5, 4:36 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 475,000 | — | — | 475,000 | — | plan? |
| Feb 8, 2016 CPForm 4 → | Feb 10, 4:32 pm EST | Hillhouse Capital Management, Ltd.10% Owner | 39,726,779 | — | — | 39,726,779 | — | plan? |
| Feb 8, 2016 CJForm 4 → | Feb 10, 4:28 pm EST | Merck & Co., Inc. +210% Owner | 31,589,038 | — | — | 7,942,314 | — | plan? |
| Feb 8, 2016 CForm 4 → | Feb 9, 8:58 pm EST | John OylerCEO, Director, 10% Owner | 9,398,380 | — | — | 59,780,349 | — | plan? |
| Feb 8, 2016 PForm 4 → | Feb 9, 8:08 pm EST | Howard LiangCFO & Chief Strategy Officer | 65,000 | $1.85 | $120,250 | 65,000 | — | plan? |
| Feb 8, 2016 PForm 4 → | Feb 9, 8:08 pm EST | RuiRong YuanChief Medical Officer | 130,000 | $1.85 | $240,500 | 130,000 | — | plan? |
| Feb 8, 2016 CForm 4 → | Feb 9, 8:07 pm EST | CB Biotech Investment Ltd +310% Owner | 19,601,138 | — | — | 19,601,138 | — | plan? |
| Feb 8, 2016 PForm 4 → | Feb 9, 5:38 pm EST | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 1,912,680 | $24.00 | $45,904,320 | 1,723,306 | — | plan? |
| Feb 8, 2016 CXForm 4 → | Feb 9, 5:38 pm EST | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 80,334,757 | $0.675 | $1,750,000 | 639,600 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 MForm 4 → | Sep 10, 4:49 pm EDT | Xiaodong WangDirector | 403,351 | — | — | 1,210,079 | — | 10b5-1 |
| Aug 11, 2026 MForm 4 → | Aug 13, 8:54 pm EDT | Chan Henry LeeSVP, General Counsel | 34,658 | — | — | 88,582 | — | 10b5-1 |
| Jul 22, 2026 MForm 4 → | Jul 24, 4:51 pm EDT | Chan Henry LeeSVP, General Counsel | 21,697 | — | — | 98,930 | — | 10b5-1 |
| Jul 20, 2026 MForm 4 → | Jul 22, 5:03 pm EDT | John OylerChief Executive Officer, Director | 441,870 | — | — | 0 | — | 10b5-1 |
| Jul 17, 2026 MForm 4 → | Jul 17, 5:36 pm EDT | John OylerChief Executive Officer, Director | 840,164 | — | — | 441,870 | — | 10b5-1 |
| Jul 15, 2026 MForm 4 → | Jul 17, 5:31 pm EDT | John OylerChief Executive Officer, Director | 3,681,002 | — | — | 1,282,034 | — | 10b5-1 |
| Jul 14, 2026 MForm 4 → | Jul 14, 9:26 pm EDT | John OylerChief Executive Officer, Director | 1,736,800 | — | — | 462,866 | — | 10b5-1 |
| Jul 10, 2026 MForm 4 → | Jul 14, 9:25 pm EDT | John OylerChief Executive Officer, Director | 782,834 | — | — | 1,264,666 | — | 10b5-1 |
| Jul 8, 2026 MForm 4 → | Jul 10, 4:44 pm EDT | Chan Henry LeeSVP, General Counsel | 8,632 | — | — | 105,300 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Lai WangPresident, Global Head of R&D | 229,775 | — | — | 229,775 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Aaron RosenbergChief Financial Officer | 137,865 | — | — | 137,865 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Xiaobin WuPresident and COO | 229,775 | — | — | 229,775 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | Chan Henry LeeSVP, General Counsel | 87,308 | — | — | 87,308 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:55 pm EDT | John OylerChief Executive Officer, Director | 344,669 | — | — | 344,669 | — | |
| Jun 11, 2026 AForm 4 → | Jun 15, 5:54 pm EDT | Xiaodong WangDirector | 193,492 | — | — | 193,492 | — | |
| Mar 11, 2019 MForm 4 → | Mar 11, 7:38 pm EDT | Jane HuangCMO, Hematology | 33,345 | — | — | 1,295,155 | — | |
| Dec 17, 2018 MForm 4 → | Dec 19, 6:34 pm EST | Amy C. PetersonCMO, Immuno-oncology | 260,000 | — | — | 820,000 | — | |
| Nov 26, 2018 MForm 4 → | Nov 28, 7:25 pm EST | Jane HuangCMO, Hematology | 39,000 | — | — | 1,328,500 | — | |
| Nov 8, 2018 MForm 4 → | Nov 13, 10:20 am EST | Amy C. PetersonCMO, Immuno-oncology | 520,000 | — | — | 1,080,000 | — | late |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:44 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 1,310,088 | — | — | 1,310,088 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:43 pm EDT | Howard LiangCFO & Chief Strategy Officer | 364,208 | — | — | 364,208 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:42 pm EDT | Jane HuangCMO, Hematology | 310,180 | — | — | 310,180 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:41 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 310,180 | — | — | 310,180 | — | |
| Jun 26, 2018 AForm 4 → | Jun 28, 7:40 pm EDT | Xiaodong WangDirector | 655,044 | — | — | 655,044 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 6:42 pm EDT | Qingqing YiDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:51 pm EDT | Donald W. GlazerDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:50 pm EDT | Timothy Yung-Cheng ChenDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 5:50 pm EDT | Thomas MalleyDirector | 17,442 | — | — | 17,442 | — | |
| Jun 6, 2018 AForm 4 → | Jun 8, 4:05 pm EDT | BAKER BROS. ADVISORS LP +5Director, 10% Owner | 34,884 | — | — | 34,884 | — | |
| Apr 30, 2018 AForm 4 → | May 2, 8:52 pm EDT | Xiaobin WuPresident & GM China | 766,599 | — | — | 766,599 | — | |
| Apr 30, 2018 AForm 4 → | May 2, 8:46 pm EDT | John OylerChief Executive Officer, Director, 10% Owner | 996,810 | — | — | 996,810 | — | |
| Apr 2, 2018 AForm 4 → | Apr 4, 4:47 pm EDT | Jingshyh S suDirector | 63,290 | — | — | 63,290 | — | |
| Mar 16, 2018 MForm 4 → | Mar 20, 5:02 pm EDT | Howard LiangCFO & Chief Strategy Officer | 455,000 | — | — | 4,445,000 | — | |
| Feb 28, 2018 MForm 4 → | Mar 2, 6:41 pm EST | Ji LiEVP and Gl. Head of Bus. Dev. | 130,000 | — | — | 2,246,000 | — | |
| Dec 21, 2017 MForm 4 → | Dec 22, 4:43 pm EST | Jane HuangCMO, Hematology | 13,000 | — | — | 1,367,500 | — | |
| Dec 13, 2017 MForm 4 → | Dec 15, 4:05 pm EST | Jane HuangCMO, Hematology | 19,500 | — | — | 1,380,500 | — | |
| Sep 27, 2017 AForm 4 → | Oct 2, 7:10 am EDT | John OylerChief Executive Officer, Director, 10% Owner | 935,000 | — | — | 935,000 | — | late |
| Sep 27, 2017 AForm 4 → | Oct 2, 6:41 am EDT | Xiaodong WangDirector | 750,000 | — | — | 750,000 | — | late |
| Jun 29, 2017 AForm 4/A → | Jun 29, 8:05 pm EDT | Howard LiangCFO & CSO | 1,250,000 | — | — | 1,250,000 | — | |
| Jun 29, 2017 AForm 4 → | Jun 29, 6:59 pm EDT | Howard LiangCFO & CSO | 1,250,000 | — | — | 1,250,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 7:04 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 1,016,178 | — | — | 1,016,178 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 7:03 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 750,000 | — | — | 750,000 | — | |
| Jun 27, 2017 AForm 4 → | Jun 29, 6:54 pm EDT | Jane HuangCMO, Hematology | 980,465 | — | — | 980,465 | — | |
| Jun 2, 2017 AForm 4 → | Jun 6, 4:29 pm EDT | Timothy Yung-Cheng ChenDirector | 169,988 | — | — | 169,988 | — | |
| Jun 2, 2017 AForm 4 → | Jun 6, 4:18 pm EDT | Thomas MalleyDirector | 169,988 | — | — | 169,988 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 5:05 pm EDT | Qingqing YiDirector | 199,992 | — | — | 199,992 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:43 pm EDT | Donald W. GlazerDirector | 199,992 | — | — | 199,992 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:42 pm EDT | Ke TangDirector | 199,992 | — | — | 199,992 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:09 pm EDT | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 399,984 | — | — | 399,984 | — | |
| Nov 16, 2016 AForm 4 → | Nov 18, 4:24 pm EST | John OylerChief Executive Officer, Director, 10% Owner | 2,047,500 | — | — | 2,047,500 | — | |
| Nov 16, 2016 AForm 4 → | Nov 18, 4:11 pm EST | Howard LiangCFO & CSO | 1,752,500 | — | — | 1,752,500 | — | |
| Nov 16, 2016 AForm 4 → | Nov 18, 4:10 pm EST | Xiaodong WangDirector | 1,613,430 | — | — | 1,613,430 | — | |
| Sep 2, 2016 AForm 4 → | Sep 7, 5:13 pm EDT | Jane HuangCMO, Hematology | 1,400,000 | — | — | 1,400,000 | — | |
| Aug 22, 2016 AForm 4 → | Aug 24, 6:12 pm EDT | Amy C. PetersonCMO, Immuno-oncology | 1,600,000 | — | — | 1,600,000 | — | |
| Jul 13, 2016 AForm 4 → | Jul 15, 4:34 pm EDT | Jianxin YangSr. VP, Head of Clinical Dev. | 825,000 | — | — | 825,000 | — | |
| Jul 13, 2016 AForm 4 → | Jul 15, 4:32 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 260,000 | — | — | 260,000 | — | |
| Jul 13, 2016 AForm 4 → | Jul 15, 4:30 pm EDT | Wendy Xiaojun YanSr. VP, Head of Reg. Affairs | 825,000 | — | — | 825,000 | — | |
| May 3, 2016 AForm 4 → | May 5, 4:36 pm EDT | Ji LiEVP and Gl. Head of Bus. Dev. | 2,376,000 | — | — | 2,376,000 | — | |
| Feb 8, 2016 CForm 4 → | Feb 10, 4:32 pm EST | Hillhouse Capital Management, Ltd.10% Owner | 30,626,779 | — | — | 0 | — | |
| Feb 8, 2016 CForm 4 → | Feb 10, 4:28 pm EST | Merck & Co., Inc. +210% Owner | 23,646,724 | — | — | 0 | — | |
| Feb 8, 2016 CXForm 4 → | Feb 9, 8:58 pm EST | John OylerCEO, Director, 10% Owner | 9,513,934 | — | — | 0 | — | |
| Feb 8, 2016 AForm 4 → | Feb 9, 8:09 pm EST | Timothy Yung-Cheng ChenDirector | 460,626 | — | — | 460,626 | — | |
| Feb 8, 2016 CForm 4 → | Feb 9, 8:07 pm EST | CB Biotech Investment Ltd +310% Owner | 19,601,138 | — | — | 0 | — | |
| Feb 8, 2016 CXForm 4 → | Feb 9, 5:38 pm EST | BAKER BROS. ADVISORS LP +6Director, 10% Owner | 80,334,757 | — | — | 0 | — |